Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Liabilities and Shareholders Equity (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $82.3 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 33.63% year-over-year to $82.3 million; the TTM value through Sep 2025 reached $308.1 million, down 5.9%, while the annual FY2024 figure was $73.4 million, 13.05% down from the prior year.
  • Liabilities and Shareholders Equity reached $82.3 million in Q3 2025 per PLX's latest filing, up from $78.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $108.2 million in Q2 2021 and bottomed at $55.8 million in Q4 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $78.3 million, with a median of $78.5 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 43.96% in 2022, then soared 54.42% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $73.7 million in 2021, then fell by 24.27% to $55.8 million in 2022, then soared by 51.35% to $84.4 million in 2023, then fell by 13.05% to $73.4 million in 2024, then increased by 12.05% to $82.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $82.3 million in Q3 2025, $78.5 million in Q2 2025, and $73.9 million in Q1 2025.